Published in J Rheumatol on January 01, 1992
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis (2007) 4.05
Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther (2006) 2.93
The nuclear receptor REV-ERBα mediates circadian regulation of innate immunity through selective regulation of inflammatory cytokines. Proc Natl Acad Sci U S A (2011) 2.38
Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis (1993) 2.05
Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis (2007) 1.44
Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention. Rheum Dis Clin North Am (2010) 1.38
Overnight variations in cortisol, interleukin 6, tumour necrosis factor alpha and other cytokines in people with rheumatoid arthritis. Ann Rheum Dis (2008) 1.19
Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors. BMC Infect Dis (2013) 1.10
Association of interleukin-6 and interleukin-10 genotypes with radiographic damage in rheumatoid arthritis is dependent on autoantibody status. Arthritis Rheum (2007) 1.07
Interleukin 6 and rheumatoid arthritis. Biomed Res Int (2014) 1.00
Local synthesis of both macrophage and T cell cytokines by synovial fluid cells from children with juvenile rheumatoid arthritis. Clin Exp Immunol (1994) 0.97
New therapies for rheumatoid arthritis. Clin Exp Immunol (2005) 0.95
Clinical significance of interleukin-6 measurement in early rheumatoid arthritis: relation with laboratory and clinical variables and radiological progression in a three year prospective study. Ann Rheum Dis (1995) 0.94
In vitro model for the analysis of synovial fibroblast-mediated degradation of intact cartilage. Arthritis Res Ther (2009) 0.93
IL-6 negatively regulates osteoblast differentiation through the SHP2/MEK2 and SHP2/Akt2 pathways in vitro. J Bone Miner Metab (2014) 0.90
-174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis. Rheumatol Int (2012) 0.88
The influence of age and gender on serum dehydroepiandrosterone sulphate (DHEA-S), IL-6, IL-6 soluble receptor (IL-6 sR) and transforming growth factor beta 1 (TGF-beta1) levels in normal healthy blood donors. Clin Exp Immunol (1999) 0.86
Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review. Patient Prefer Adherence (2013) 0.86
Cytokines and soluble CD4 and CD8 molecules in rheumatoid arthritis: relationship to systematic vasculitis and microvascular capillaroscopic abnormalities. Clin Rheumatol (1998) 0.86
Interleukin 6 receptor as a target for the treatment of rheumatoid arthritis. Ann Rheum Dis (2003) 0.84
Effect of cyclosporin A on interleukin-6 and soluble interleukin-2 receptor in patients with rheumatoid arthritis. Ann Rheum Dis (1995) 0.81
Suppression of human macrophage interleukin-6 by a nonpsychoactive cannabinoid acid. Rheumatol Int (2007) 0.80
Adenosine A2A receptor and TNF-α regulate the circadian machinery of the human monocytic THP-1 cells. Inflammation (2013) 0.78
Animal Models of Bone Loss in Inflammatory Arthritis: from Cytokines in the Bench to Novel Treatments for Bone Loss in the Bedside-a Comprehensive Review. Clin Rev Allergy Immunol (2016) 0.76
Chlorogenic acid induces apoptosis to inhibit inflammatory proliferation of IL-6-induced fibroblast-like synoviocytes through modulating the activation of JAK/STAT and NF-κB signaling pathways. Exp Ther Med (2016) 0.76
The -174G/C Interleukin-6 Gene Promoter Polymorphism as a Genetic Marker of Differences in Therapeutic Response to Methotrexate and Leflunomide in Rheumatoid Arthritis. Biomed Res Int (2016) 0.75
Serial estimation of serum interleukin 6 during treatment with recombinant human erythropoietin in patients with the anemia of rheumatoid arthritis. J Rheumatol (1993) 0.75
SH3--an abundant protein domain in search of a function. FEBS Lett (1992) 12.98
Rheumatoid arthritis: a disease of T-lymphocyte/macrophage immunoregulation. Lancet (1981) 6.62
American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) (2012) 4.82
The PH domain: a common piece in the structural patchwork of signalling proteins. Trends Biochem Sci (1993) 3.89
Injuries in Rugby Union football. Br Med J (1979) 3.65
The SANT domain: a putative DNA-binding domain in the SWI-SNF and ADA complexes, the transcriptional co-repressor N-CoR and TFIIIB. Trends Biochem Sci (1996) 3.55
The preferential accumulation of helper-inducer T lymphocytes in inflammatory lesions: evidence for regulation by selective endothelial and homotypic adhesion. Eur J Immunol (1988) 3.05
The gene mutated in ataxia-ocular apraxia 1 encodes the new HIT/Zn-finger protein aprataxin. Nat Genet (2001) 3.01
Immunohistological analysis of delayed-type hypersensitivity in man. Cell Immunol (1982) 2.86
The phototrophic bacterium Rhodopseudomonas capsulata sp108 encodes an indigenous class A beta-lactamase. Biochem J (1989) 2.44
A regular pattern of two types of 100-residue motif in the sequence of titin. Nature (1990) 2.29
Ankylosing spondylitis, HLA-B27 and Klebsiella. I. Cross-reactivity studies with rabbit antisera. Br J Exp Pathol (1980) 2.16
Risk of schizophrenia in adults born after obstetric complications and their association with early onset of illness: a controlled study. BMJ (1992) 2.03
A new method for isolating tyrosine kinase substrates used to identify fish, an SH3 and PX domain-containing protein, and Src substrate. EMBO J (1998) 2.01
An evaluated programme of rheumatology training for general practitioners. Br J Rheumatol (1986) 1.88
Evidence that nebulin is a protein-ruler in muscle thin filaments. FEBS Lett (1991) 1.87
Use of simple analgesics in rheumatoid arthritis. Ann Rheum Dis (1985) 1.84
HLA-B27 and the immune response to enterobacterial antigens in ankylosing spondylitis. Clin Exp Immunol (1984) 1.79
Targeted therapies in rheumatoid arthritis: the need for action. Rheumatology (Oxford) (1999) 1.78
The efficacy of lower axillary sampling in obtaining lymph node status in breast cancer: a controlled randomized trial. Br J Surg (1985) 1.78
Histochemical discrimination of HLA-DR positive cell populations in the normal and arthritic synovial lining. Clin Exp Immunol (1982) 1.75
Controlled comparison of short-wave diathermy treatment with osteopathic treatment in non-specific low back pain. Lancet (1985) 1.74
Zinc finger-DNA recognition: analysis of base specificity by site-directed mutagenesis. Nucleic Acids Res (1992) 1.74
Closure of rhomboid skin defects: the flaps of Limberg and Dufourmentel. Br J Plast Surg (1972) 1.68
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis (2012) 1.67
Outpatient lumbar epidural corticosteroid injection in the management of sciatica. Br J Rheumatol (1988) 1.67
Nervous system involvement in systemic lupus erythematosus. Ann Rheum Dis (1975) 1.67
The T-cell-receptor repertoire in the synovial fluid of a patient with rheumatoid arthritis is polyclonal. Proc Natl Acad Sci U S A (1991) 1.67
Allopurinol treatment and its effect on renal function in gout: a controlled study. Ann Rheum Dis (1982) 1.65
Quinidine elimination in patients with congestive heart failure or poor renal function. N Engl J Med (1974) 1.63
The diagnosis of Poncet's disease. Br J Rheumatol (1993) 1.62
Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab. Br J Dermatol (2004) 1.61
Homology between two EBV early genes and HSV ribonucleotide reductase and 38K genes. Nucleic Acids Res (1984) 1.57
Subclinical liver disease in systemic lupus erythematosus. J Rheumatol (1982) 1.57
The involvement of interdigitating (antigen-presenting) cells in the pathogenesis of rheumatoid arthritis. Clin Exp Immunol (1983) 1.56
Letter: Localized hypertrophic osteoarthropathy with abdominal aortic prosthesis and infection. Ann Intern Med (1974) 1.51
High-affinity RNA ligands to Escherichia coli ribosomes and ribosomal protein S1: comparison of natural and unnatural binding sites. Biochemistry (1995) 1.50
DNA-binding domain ancestry. Nature (1989) 1.49
Abnormal distribution of the helper-inducer and suppressor-inducer T-lymphocyte subsets in the rheumatoid joint. Clin Immunol Immunopathol (1987) 1.47
A comparison of the clinical features of hospital out-patients with rheumatoid disease and osteoarthritis in Pakistan and England. Br J Rheumatol (1996) 1.46
Towards a structural understanding of Friedreich's ataxia: the solution structure of frataxin. Structure (2000) 1.46
CSF findings in 250 patients with serologically confirmed West Nile virus meningitis and encephalitis. Neurology (2005) 1.45
Clinical associations of anti-lamin autoantibodies. Aust N Z J Med (1996) 1.39
Notes on the Medical History of Kingston. Can Med Assoc J (1928) 1.39
Adalimumab-induced asthma. Rheumatology (Oxford) (2005) 1.38
Gout and hyperlipidaemia. Ann Rheum Dis (1974) 1.37
Antigen-induced IL-17 response in the peripheral blood mononuclear cells (PBMC) of healthy controls. Clin Exp Immunol (2000) 1.35
Serum methylprednisolone levels following intra-articular injection of methylprednisolone acetate. Ann Rheum Dis (1981) 1.35
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis (2010) 1.34
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis (2008) 1.31
Season of birth in schizophrenia. Evidence for confinement of an excess of winter births to patients without a family history of mental disorder. Br J Psychiatry (1991) 1.29
Dissecting FMR1, the protein responsible for fragile X syndrome, in its structural and functional domains. RNA (1999) 1.26
The value of exercises in the treatment of low back pain. Rheumatol Rehabil (1979) 1.24
Prevalence of the major rheumatic disorders in the adult population of north Pakistan. Br J Rheumatol (1998) 1.23
Cytology of rheumatoid synovial cells in culture. I. Composition and sequence of cell populations in cultures of rheumatoid synovial fluid. Ann Rheum Dis (1974) 1.21
Intramuscular depot methylprednisolone induction of chrysotherapy in rheumatoid arthritis: a 24-week randomized controlled trial. Br J Rheumatol (1990) 1.20
Dermatomyositis with lung involvement in a patient treated with simvastatin. Aust N Z J Med (1995) 1.18
Chronic low back pain: comparison of bone SPECT with radiography and CT. Radiology (1992) 1.18
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis (2011) 1.17
Mechanisms of depressed delayed-type hypersensitivity in rheumatoid arthritis: the role of protein energy malnutrition. Ann Rheum Dis (1984) 1.16
Solution structure of the basic region from the transcriptional activator GCN4. Biochemistry (1991) 1.15
Effect of intra-articular corticosteroid injections on primate cartilage. Ann Rheum Dis (1977) 1.14
Sacroiliitis presenting as sciatica. Rheumatology (Oxford) (2005) 1.14
A controlled trial of sulphasalazine treatment of chronic ankylosing spondylitis: failure to demonstrate a clinical effect. Br J Rheumatol (1990) 1.14
A controlled study of diet in patients with gout. Ann Rheum Dis (1983) 1.14
Local injection treatment of tennis elbow--hydrocortisone, triamcinolone and lignocaine compared. Br J Rheumatol (1991) 1.13
The lupus coagulation inhibitor and venous thrombosis: a report of four cases. Clin Lab Haematol (1980) 1.13
Mechanism and treatment of hypertriglyceridaemia in gout. Ann Rheum Dis (1979) 1.11
Biomechanical properties of skin. Surg Clin North Am (1967) 1.10
Azapropazone--a treatment for hyperuricaemia and gout? Br J Rheumatol (1984) 1.10
The mobile micro-architecture of dermal collagen: a bio-engineering study. Br J Surg (1965) 1.10
The value of SPECT scans in identifying back pain likely to benefit from facet joint injection. Br J Rheumatol (1996) 1.09
Recognition of the mRNA selenocysteine insertion sequence by the specialized translational elongation factor SELB. Genes Dev (1994) 1.09
Formin defines a large family of morphoregulatory genes and functions in establishment of the polarising region. Cell Tissue Res (1999) 1.08
The KH module has an alpha beta fold. FEBS Lett (1995) 1.08
Production of human monoclonal IgG and IgM antibodies with anti-D (rhesus) specificity using heterohybridomas. Immunology (1986) 1.06
Neuronal cell loss in the CA3 subfield of the hippocampus following cortical contusion utilizing the optical disector method for cell counting. J Neurotrauma (1997) 1.04
A 10 year prospective followup of patients with rheumatoid arthritis 1986-96. J Rheumatol (2001) 1.03
Directional variation in extensibility of human skin in vivo. J Biomech (1969) 1.03
Clotrimazole in rheumatoid arthritis. Ann Rheum Dis (1980) 1.02
Nature of the ribosomal mRNA track: analysis of ribosome-binding sites containing different sequences and secondary structures. Biochemistry (1993) 1.02
Structure of murine complement component C3. II. Nucleotide sequence of cloned complementary DNA coding for the alpha chain. J Biol Chem (1984) 1.01
Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure. Rheumatology (Oxford) (2005) 1.01
Requirements for the establishment of heterohybridomas secreting monoclonal human antibody to rhesus (D) blood group antigen. J Immunol Methods (1987) 1.01
Hyperuricaemia, gout and kidney function in New Zealand Maori men. Br J Rheumatol (1984) 1.01
Polychlorinated biphenyl congeners in blood of Wisconsin sport fish consumers. Arch Environ Contam Toxicol (1991) 1.01
Corticosteroids inhibit lymphocyte binding to endothelium and intercellular adhesion: an additional mechanism for their anti-inflammatory and immunosuppressive effect. J Immunol (1997) 1.00
Biomechanical characteristics of human skin and costal cartilage. Fed Proc (1966) 0.99
The solution structure of a leucine-zipper motif peptide. Protein Eng (1991) 0.99
Changes in immune function in patients with rheumatoid arthritis following treatment with sodium aurothiomalate. Ann Rheum Dis (1981) 0.99
A comparison of the prevalence of rheumatoid arthritis and other rheumatic diseases amongst Pakistanis living in England and Pakistan. Br J Rheumatol (1997) 0.98
Diurnal variation in insulin sensitivity. Lancet (1972) 0.98
Evidence that D-penicillamine alters the course of rheumatoid arthritis. Rheumatol Rehabil (1976) 0.97
Day and night pain measurement in rheumatoid arthritis. Ann Rheum Dis (1998) 0.97
The diagnostic value of synovial biopsy in patients with arthritis of unknown cause. Br J Rheumatol (1985) 0.97
Infliximab improves vascular stiffness in patients with rheumatoid arthritis. Ann Rheum Dis (2008) 0.96
Laparoscopic colon resections: a five-year retrospective review. Am Surg (2000) 0.96